Roche Says MS Drug Ocrevus Launch Its 'Best So Far', Vows To Help US Reform
Executive Summary
Roche said MS drug Ocrevus should generate sales of CHF2bn in its first full year after launch. The Swiss group also pledged to actively help the Trump Administration with its healthcare reform program.
You may also be interested in...
Roche Says New Drugs Can Allow Safe Navigation Despite Biosimilar Threats
Swiss group raises guidance for second time this year despite looming biosimilar competition and Cabilly patent loss.
All Systems Go as Roche MS Drug Ocrevus Secures EU Okay At Last
Now that the European Commission has finally given the go-ahead to Ocrevus, regarded by multiple sclerosis specialists as a game changer especially for the primary progressive form of the disease, observers will be watching to see what pricing strategy Roche adopts.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.